Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date	Title and Summary	View
Oct 14, 2021	PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2021 Financial Results SOUTH PLAINFIELD, N.J. , Oct. 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2021 financial results and provide an update on the company's business and outlook on Thursday, Oct.	Additional Formats
Oct 14, 2021	PTC Therapeutics Celebrates Opening of Gene Therapy Manufacturing Facility -- Expansion in New Jersey supports company's robust gene therapy pipeline to address devastating rare disorders -- SOUTH PLAINFIELD, N.J. , Oct. 14, 2021 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) will host a ribbon-cutting ceremony to recognize the official opening of its new gene	Additional Formats
Oct 11, 2021	Tegsedi® Receives Innovative Drug Category Pricing in Brazil SOUTH PLAINFIELD, N.J. , Oct. 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Tegsedi ® (inotersen) has successfully received Category 1 classification from Câmara de Regulação do Mercado de Medicamentos - CMED (Drug Market Regulation Chamber) in Brazil .	Additional Formats
Sep 29, 2021	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH PLAINFIELD, N.J. , Sept. 29, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept. 22, 2021, the company approved non-statutory stock options to purchase an aggregate of 51,400 shares of its common stock and 18,790 restricted stock units ("RSUs"), each	Additional Formats
Sep 29, 2021	Results Show Long-Lasting and Holistic Improvements in Children with AADC Deficiency Treated with PTC-AADC Gene Therapy - Analysis of Five-Year Results Presented at 50th Child Neurology Society Annual Meeting - SOUTH PLAINFIELD, N.J. , Sept. 29, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented a new analysis of five-year results that shows its novel gene therapy, PTC-AADC,	Additional Formats
Sep 20, 2021	PTC Therapeutics to Host Conference Call to Discuss Results of PTC518 Phase 1 Study for Huntington's Disease Program SOUTH PLAINFIELD, N.J. , Sept. 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call to discuss the positive results from the PTC518 Phase 1 healthy volunteer study. The new results include HTT mRNA and protein lowering, as well as PTC518 exposure levels in	Additional Formats
Sep 20, 2021	STRIDE Data Show Translarna™ Delays Loss of Ambulation by More Than Five Years in Boys with Nonsense Mutation Duchenne Muscular Dystrophy - Translarna was seen to slow disease progression compared to standard of care alone - - Data from long-term, real-world results from 241 patients in the STRIDE* patient registry - SOUTH PLAINFIELD, N.J. , Sept. 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc.	Additional Formats
Sep 07, 2021	PTC Therapeutics Recognizes 2021 STRIVE Awards Recipients for Initiatives Supporting Duchenne Patient Community - Patient Advocacy Organizations in Brazil and the U.K. Awarded Funding - SOUTH PLAINFIELD, N.J. , Sept. 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the three recipients who will receive funding through the company's STRIVE Awards program.	Additional Formats
Aug 27, 2021	PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences SOUTH PLAINFIELD, N.J. , Aug. 27, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Morgan Stanley Virtual 19 th Annual Global Healthcare Conference Friday, September 10 th at 11:00 a.m.	Additional Formats
Aug 23, 2021	PTC Therapeutics Announces Waylivra™ Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome - Approval Addresses Unmet Needs of Patients with No Other Treatment Options - SOUTH PLAINFIELD, N.J. , Aug. 23, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved	Additional Formats